Drug Profile
Tumour infiltrating lymphocytes - Iovance Biotherapeutics/H Lee Moffitt Cancer Center and Research Institute
Alternative Names: TIL - Iovance Biotherapeutics/H. Lee Moffitt Cancer Center and Research InstituteLatest Information Update: 04 Aug 2023
Price :
$50
*
At a glance
- Originator Iovance Biotherapeutics
- Developer Bristol-Myers Squibb; H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics; The V Foundation for Cancer Research
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-small cell lung cancer
- No development reported Malignant melanoma; Sarcoma
Most Recent Events
- 04 Aug 2023 Tumor-infiltrating Lymphocytes are still in phase I trials for Non Small Cell Lung Cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (NCT03215810)
- 09 Jun 2023 Iovance Biotherapeutics completes a phase I trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (IV) (NCT03215810)
- 28 May 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)